Editor's Note: Marc Chaikin's last major recommendation for our readers drew a huge response. Today he's back with a new #1 retirement pick — and he's sharing the details free, no email or credit card required.

Dear Reader,

In 2014, I recommended my readers put a big chunk of their retirement money into one stock: Nvidia.

Anyone who followed that recommendation is up more than 45,000% at this point.

I've spent 60 years on Wall Street. I built one of Wall Street's most well-known tools – Chaikin Money Flow indicator. Even Jim Cramer said he's learned never to bet against me given my decades long track record of picking stock market winners.

Now I've unearthed what I believe could be an even better retirement stock for the years ahead — and today I'm going to share the details, totally free of charge. (Click here to get the specifics.)

Here's the single biggest reason why.

This company is sitting on three fast-growing businesses, and each one could be spun off into a separate publicly traded company. If that happens — and I believe the next 12 to 24 months are when it could — anyone holding this stock beforehand could have those spinoff shares deposited into their account automatically.

In other words, one ticker today could become three tickers tomorrow. That's the kind of setup that almost never appears in a stock this size.

And Wall Street still considers this company a "dark horse" in the AI race.

It shouldn't when its autonomous vehicle division is already being called the "undisputed leader" against Tesla. And it's streaming service has 10X greater reach than Netflix.

Yet most investors have no idea it's even in those businesses.

The market is pricing this as one ordinary company instead of three extraordinary ones.

There's also a dividend — which is rare for a high-growth technology company. Most AI names pay nothing at all.

In my new presentation, I explain everything you need to know — including why a major event that just occurred in AI's frontier labs put this company at the top of my buy list.

That's why I believe this might be the greatest retirement stock in America right now.

Click here to get the details of this amazing stock, totally free of charge.

No credit card, no email required.

Sincerely,

Marc Chaikin
Founder, Chaikin Analytics

P.S. A high-growth tech stock that pays a dividend is a rarity — this one is the exception. To be in line and claim your share of the next $2.6 billion payout, you need to own at least one share by September 4th. Click here so you don't miss the cutoff.

2 Biotech Stocks Shaping Up for Major Breakouts

By Ryan Hasson. Originally Published: 8/22/2026.

The biotech sector just received the kind of catalyst that can define a cycle. On Wednesday, Moderna (NASDAQ: MRNA) stunned the market when its personalized mRNA cancer vaccine, developed with Merck (NYSE: MRK), became the first such therapy to succeed in a late-stage trial, reducing the risk of melanoma recurrence.

The stock closed up an astonishing 177%, and the implications stretch far beyond a single company. The result marked a landmark validation of the broader mRNA platform and could represent a turning point for cancer treatment itself.

The news landed as the sector was already surging. The iShares Biotechnology ETF (NASDAQ: IBB) is up about 25% year to date, with much of that growth coming in the last 30 days, when it reached a fresh 52-week high. That strength is the kind of momentum that tends to draw fresh money off the sidelines. With Moderna's breakthrough adding fuel to the rally, biotech's leadership may only strengthen from here.

Two biotech names that have quietly built powerful uptrends throughout this run and now appear poised for breakouts are Eli Lilly (NYSE: LLY) and Natera (NASDAQ: NTRA).

Eli Lilly: The Pharma Giant Still Dominating Its Market

Eli Lilly is the world's largest pharmaceutical company by market capitalization, a $1.2 trillion healthcare titan anchored by its blockbuster GLP-1 franchise. Even at that scale, the stock continues to climb, rising more than 15% year to date and jumping about 4% on Wednesday alone to close just below its 52-week high.

The latest catalyst is Lilly's push into oral GLP-1 medications, a next-generation format that could dramatically expand the weight-loss and diabetes market beyond today's injectables and open the door to hundreds of millions of new patients.

That opportunity builds on an already dominant foundation, as Lilly's existing treatments continue to outpace rival Novo Nordisk (NYSE: NVO) in sales growth. A company of this size rarely has both entrenched market leadership and a genuine new growth vector at the same time, but Lilly has exactly that.

On the analyst front, Lilly has a Moderate Buy consensus among 30 analysts, and its news sentiment score ranks among the strongest in large-cap healthcare. The stock reached a new 52-week high on Wednesday, breaking above a resistance level that had held for almost three months. If the stock can hold above $1,250, a major prior resistance level, a significantly higher-timeframe breakout could be in the cards for this sector-leading giant.

Natera: The Genetic Testing Leader Firing on All Cylinders

Natera offers a very different profile: It is a fast-growing diagnostics innovator specializing in cell-free DNA testing across reproductive health, oncology and organ transplantation. Its Signatera cancer-monitoring assay has become a standout product, and the company sits directly in the path of the precision-medicine wave sweeping through healthcare.

Natera has soared more than 40% year to date, easily outpacing the sector benchmark. Since breaking out of its multimonth base in June, the stock has continued its powerful advance, driven by accelerating revenue growth. Annual sales now top $2.3 billion.

The market is treating Natera as a genuine leader in its niche, and its status as a top-10 holding in the IBB underscores that standing.

Analysts remain constructive, with a Moderate Buy consensus from 22 analysts. Just last week, Citi reiterated a Buy rating on the stock and raised its price target from $315 to $365.

The one factor worth flagging is valuation. After such a run, Natera trades at a rich multiple of more than 20 times sales, making it a momentum-driven growth name rather than a value play. From a momentum perspective, the chart is also shaping up for another potential breakout. Following its recent earnings report, the stock has spent several weeks consolidating near its 52-week high and building a tight base. If NTRA pushes through that high, it could signal a breakout, with further upward momentum potentially following as the uptrend continues to expand.

2 Leaders at a Pivotal Moment

What makes these two names compelling right now is timing. Both have already demonstrated their strength through months of outperformance, and both enter this moment with sector-wide momentum at their backs following Moderna's historic breakthrough. Eli Lilly offers scale, dominance and a fresh oral-drug catalyst, while Natera brings explosive growth and leadership in precision diagnostics. With biotech breaking out as a group and these two stocks pressing against their highs, the setup is one worth watching closely. As always, the charts will tell the final story, but the fundamental and sector backdrop could hardly be more supportive.